Ann: Opthea Announces Decision to Discontinue Wet AMD Trials, page-77

This is certainly a very important and scientifically interesting question and I suspect the clinicians involved in the trial will be spending the next few years trying to workout what happened, but none of this matters to OPT. No matter the cause this is the end of the road for OPT-302 and OPT.

One other factor I thought of that might have messed up the trial is the rise of the GLP-1 agonists (Ozempic). If a significant percentage of patients on the trial started taking Ozempic then this may have resulted in the huge jump in efficacy of the VEGF A/B treatments. Another easily tested hypothesis.